In addition to the importance of Gal-3 as a diagnostic and prognostic biomarker for atherosclerotic disease and heart failure, Gal-3 may also be a potential target for pharmacological treatment to inhibit inflammatory and fibrotic tissue processes. The gene discussed is LGALS3; the disease is heart failure.